Eric A. Espiner

TL;DR: Plasma N-BNP measured 2 to 4 days after myocardial infarction independently predicted left ventricular function and 2-year survival and Stratification of patients into low- and high-risk groups can be facilitated by plasma natriuretic peptide or BNP measurements, and one of these could reasonably be included in the routine clinical workup of patients after my cardiac infarctions.

TL;DR: The finding that plasma BNP is raised in Dyspnoeic patients with HF but not in acutely breathless patients with PLD, suggests that rapid BNP assays may assist in the diagnosis of patients with acute dyspnoea.

TL;DR: Plasma N-BNP (or BNP) and LVEF are complementary independent predictors of major adverse events on follow-up after myocardial infarction and combined measurement provides risk stratification substantially better than that provided by either alone.

TL;DR: In patients with established ischemic LV dysfunction, plasma N-BNP and adrenomedullin are independent predictors of mortality and heart failure.

TL;DR: It is shown that hBNP, at plasma levels observed in patients with mild heart failure, has potentially important natriuretic, endocrine, and hemodynamic effects which are similar to those observed with comparable infusion rates of ANF.